ES8802493A1 - Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos. - Google Patents

Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.

Info

Publication number
ES8802493A1
ES8802493A1 ES557642A ES557642A ES8802493A1 ES 8802493 A1 ES8802493 A1 ES 8802493A1 ES 557642 A ES557642 A ES 557642A ES 557642 A ES557642 A ES 557642A ES 8802493 A1 ES8802493 A1 ES 8802493A1
Authority
ES
Spain
Prior art keywords
amide derivatives
heterocyclic amide
compound
formula
benzoheterocyclylalkanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES557642A
Other languages
English (en)
Other versions
ES557642A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeneca Inc
Original Assignee
ICI Americas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858509882A external-priority patent/GB8509882D0/en
Priority claimed from GB858525658A external-priority patent/GB8525658D0/en
Application filed by ICI Americas Inc filed Critical ICI Americas Inc
Publication of ES557642A0 publication Critical patent/ES557642A0/es
Publication of ES8802493A1 publication Critical patent/ES8802493A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

LAS AMIDAS DE ACIDOS BENZOHETEROCICLILALCANOICOS (I), DONDE NO EXCLUSIVAMENTE, >X-Y-Z- ES >C=N-ZA, ->N-N=NO >N-CRA=N-, CON RA ALQUILO C1-4 R1L ES RADICAL AMIDICO, CON ALQUILO C2-10, R2 ALQUILO O ALCOXI C1-4, A1 ALQUILENO C1-2 O VINILENO, A2 METILENO, M CARBOXI Y Q FENILENO; SE OBTIENEN HIDROLIZANDO EN CONDICIONES ACIDAS O BASICAS UN ESTER (II), SIENDO RB ALQUILO C1-6, ENTRE 15 Y 100GC, OBTENIENDOSE POR REACCION CON UNA BASE LA SAL FARMACEUTICAMENTE ACEPTABLE. PRESENTAN PROPIEDADES ANTAGONISTAS DE LOS LEUCOTRIENOS Y SON APLICABLES AL TRATAMIENTO DE ENFERMEDADES ALERGICAS O INFLAMATORIAS, EN ESTADO DE SHOCK ENDOTOXICO O TRAUMATICO. *FORMULA*
ES557642A 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos. Expired ES8802493A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858509882A GB8509882D0 (en) 1985-04-17 1985-04-17 Heterocyclic amide derivatives
GB858525658A GB8525658D0 (en) 1985-10-17 1985-10-17 Heterocyclic amide derivatives

Publications (2)

Publication Number Publication Date
ES557642A0 ES557642A0 (es) 1988-07-16
ES8802493A1 true ES8802493A1 (es) 1988-07-16

Family

ID=26289139

Family Applications (6)

Application Number Title Priority Date Filing Date
ES000554027D Expired - Lifetime ES8802220B9 (es) 1985-04-17 1986-04-16 "procedimiento para la obtencion de amidas de acidos benzoheterociclillcanoicos".
ES554027A Expired ES8802220A1 (es) 1985-04-17 1986-04-16 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.
ES557643A Expired ES8802494A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de derivados de acidos benzoheterociclilalcanoicos
ES557642A Expired ES8802493A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.
ES557644A Expired ES8802023A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos
ES557645A Expired ES8801787A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES000554027D Expired - Lifetime ES8802220B9 (es) 1985-04-17 1986-04-16 "procedimiento para la obtencion de amidas de acidos benzoheterociclillcanoicos".
ES554027A Expired ES8802220A1 (es) 1985-04-17 1986-04-16 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.
ES557643A Expired ES8802494A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de derivados de acidos benzoheterociclilalcanoicos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES557644A Expired ES8802023A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos
ES557645A Expired ES8801787A1 (es) 1985-04-17 1987-07-31 Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos

Country Status (26)

Country Link
US (6) US4859692A (es)
EP (1) EP0199543B1 (es)
JP (2) JPH0667904B2 (es)
KR (1) KR900004384B1 (es)
CN (1) CN1017425B (es)
AR (1) AR242569A1 (es)
AU (1) AU596582B2 (es)
BG (1) BG60471B2 (es)
CA (1) CA1340567C (es)
CS (1) CS399791A3 (es)
CY (1) CY1705A (es)
DE (1) DE3682698D1 (es)
DK (1) DK167354B1 (es)
ES (6) ES8802220B9 (es)
FI (1) FI83865C (es)
GB (1) GB8607294D0 (es)
HK (1) HK120994A (es)
HU (1) HU196968B (es)
IE (1) IE59140B1 (es)
IL (1) IL78569A (es)
NO (1) NO171452C (es)
NZ (1) NZ215850A (es)
PH (1) PH26763A (es)
PT (1) PT82389B (es)
SA (1) SA93140396A (es)
ZW (1) ZW8786A1 (es)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179112A (en) * 1985-04-17 1993-01-12 Ici Americas Inc. Heterocyclic amide derivatives and pharmaceutical use
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
IL80336A (en) * 1985-10-17 1990-02-09 Ici America Inc Indole or benzopyrazole derivatives,their preparation and pharmaceutical compositions containing them
ZA892643B (en) * 1988-04-14 1989-12-27 Ici America Inc Carbocyclic compounds
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
DK0455596T3 (da) * 1990-05-04 1994-11-28 Ciba Geigy Ag Substituerede indoler
GB9026427D0 (en) * 1990-12-05 1991-01-23 Ici Plc Chemical process
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
DE69212058T2 (de) * 1991-03-11 1997-01-09 Kyowa Hakko Kogyo Kk Indol-Derivate
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5334597A (en) * 1991-10-17 1994-08-02 Merck Frosst Canada, Inc. Indole carbamates as leukotriene antagonists
DE59202229D1 (de) * 1991-10-25 1995-06-22 Ciba Geigy Ag Verfahren zur Herstellung substituierter Indole.
EP0539329A1 (de) * 1991-10-25 1993-04-28 Ciba-Geigy Ag Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten
US5272169A (en) * 1992-03-27 1993-12-21 The Dupont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
US5217983A (en) * 1992-03-27 1993-06-08 Du Pont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
GB9207236D0 (en) * 1992-04-02 1992-05-13 Grosvenor Power Services Ltd Treatment of liquids
US5280039A (en) * 1992-11-04 1994-01-18 Pfizer Inc. Bicyclic carbamates and methods of treating inflammatory diseases using the same
US5439929A (en) * 1994-03-01 1995-08-08 Pfizer Inc. Bicyclic carbamates, pharmaceutical compositions and use
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
ES2108641B1 (es) * 1995-07-31 1998-08-16 Menarini Lab Sulfonimidas quinolonicas con accion antagonista de los leucotrienos.
CZ248798A3 (cs) * 1996-02-08 1999-01-13 Merck And Co., Inc. Farmaceutický prostředek
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
CA2317439A1 (en) 1998-01-14 1999-07-22 Wayne J. Brouillette Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EE200000573A (et) 1998-03-31 2002-04-15 The Institutes For Pharmaceutical Discovery, Llc Asendatud indoolalkaanhapped
DE19821002A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6194432B1 (en) * 1998-10-13 2001-02-27 Fred D. Sheftell Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU6315300A (en) * 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
KR101004187B1 (ko) * 2003-01-13 2010-12-24 다이닛본 스미토모 세이야꾸 가부시끼가이샤 1,2-디클로로에탄 프리 조니사미드 결정 및 고순도조니사미드 결정의 제조방법
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
EP1817034A1 (en) 2004-10-25 2007-08-15 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
RU2416601C2 (ru) * 2005-02-25 2011-04-20 Оно Фармасьютикал Ко., Лтд. Соединение индола и его применение
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007096694A1 (es) * 2006-02-22 2007-08-30 Ramiro Vergara Asociacion de principios activos neuroactivadores
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
WO2008000760A1 (en) * 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
JP2009543839A (ja) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性の性的障害を治療するためのフリバンセリンの使用
CN101104601B (zh) * 2006-07-14 2011-01-26 海南盛科生命科学研究院 一种新的扎鲁司特重要中间体的制备方法
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2054041A2 (en) * 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
CN101505736A (zh) * 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2170825A2 (en) * 2007-07-30 2010-04-07 Auspex Pharmaceuticals, Inc. Substituted indoles
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US20100022613A1 (en) * 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
WO2010085820A2 (en) * 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) * 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
JP2018531957A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
EP3168570A1 (fr) 2015-11-10 2017-05-17 Primetals Technologies France SAS Méthode de mesure de planéité d'un produit métallique et dispositif associé
KR101713303B1 (ko) * 2015-12-24 2017-03-07 강원대학교산학협력단 2ｈ-인다졸 유도체의 제조방법
JP7272655B2 (ja) 2017-01-30 2023-05-12 ウェスタン ニュー イングランド ユニバーシティ チオールイソメラーゼ阻害剤およびその使用
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
CN109438414B (zh) * 2018-10-24 2021-03-16 常州大学 一种制备苯并1,3-氧硫杂环己烷-4-酮的方法
CN110183371B (zh) * 2019-04-11 2022-06-14 南京医科大学 一种扎鲁司特中间体的制备工艺
US20220401411A1 (en) 2019-10-08 2022-12-22 Rigshospitalet Zafirlukast derivatives for use as contraceptive agents
EP4340828A1 (en) 2021-05-19 2024-03-27 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2381935A (en) * 1940-11-16 1945-08-14 Eastman Kodak Co Process for producing morpholine compounds
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
GB1050302A (es) * 1964-02-19
FR4035M (es) * 1964-11-04 1966-03-28
DE1769018A1 (de) * 1968-03-21 1971-06-09 Bayer Ag Azofarbstoffe und Verfahren zu ihrer Herstellung
FR7631M (es) * 1968-08-13 1970-01-26
US3470298A (en) * 1969-01-29 1969-09-30 Acraf Topical anti-inflammatory composition containing (indazole-3-yl)-oxyalkanoic acids
BE738727A (en) * 1969-09-11 1970-02-16 Anti inflammatory analgesic and antipyretic indolyalkanoic - acids and derivs
DE2854987A1 (de) * 1978-12-20 1980-06-26 Boehringer Mannheim Gmbh Diagnostische mittel zum nachweis proteolytischer enzyme und dafuer geeignete chromogene
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids

Also Published As

Publication number Publication date
ES8802220A1 (es) 1988-04-16
EP0199543B1 (en) 1991-12-04
DE3682698D1 (de) 1992-01-16
CA1340567C (en) 1999-06-01
CY1705A (en) 1994-01-14
BG60471B2 (bg) 1995-04-28
FI861601A0 (fi) 1986-04-16
US5440035A (en) 1995-08-08
JPS6293274A (ja) 1987-04-28
NO171452C (no) 1993-03-17
NO171452B (no) 1992-12-07
HU196968B (en) 1989-02-28
PT82389B (pt) 1988-08-17
ES8802023A1 (es) 1988-03-16
JPH0742270B2 (ja) 1995-05-10
FI861601A (fi) 1986-10-18
PT82389A (en) 1986-05-01
ZW8786A1 (en) 1987-11-04
US5391758A (en) 1995-02-21
KR900004384B1 (ko) 1990-06-23
DK173486A (da) 1986-10-18
ES8802494A1 (es) 1988-07-16
EP0199543A2 (en) 1986-10-29
FI83865C (fi) 1991-09-10
DK167354B1 (da) 1993-10-18
US4859692A (en) 1989-08-22
EP0199543A3 (en) 1988-10-26
AU5616486A (en) 1986-10-23
GB8607294D0 (en) 1986-04-30
PH26763A (en) 1992-09-28
ES557642A0 (es) 1988-07-16
CN1017425B (zh) 1992-07-15
AR242569A1 (es) 1993-04-30
KR860008136A (ko) 1986-11-12
CN86103278A (zh) 1986-12-17
ES8802220B9 (es) 2012-01-03
AU596582B2 (en) 1990-05-10
ES557644A0 (es) 1988-03-16
HUT40623A (en) 1987-01-28
IE861000L (en) 1986-10-17
SA93140396A (ar) 2005-12-03
NZ215850A (en) 1990-03-27
US5583152A (en) 1996-12-10
IE59140B1 (en) 1994-01-12
US5030643A (en) 1991-07-09
JPH06279404A (ja) 1994-10-04
JPH0667904B2 (ja) 1994-08-31
ES557643A0 (es) 1988-07-16
ES557645A0 (es) 1988-02-16
DK173486D0 (da) 1986-04-16
ES554027A0 (es) 1988-04-16
NO861481L (no) 1986-10-20
ES8801787A1 (es) 1988-02-16
IL78569A0 (en) 1986-08-31
HK120994A (en) 1994-11-11
US5338734A (en) 1994-08-16
FI83865B (fi) 1991-05-31
CS399791A3 (en) 1992-09-16
IL78569A (en) 1990-02-09

Similar Documents

Publication Publication Date Title
ES8802493A1 (es) Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.
ZA918893B (en) Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives,process for their production and pharmaceutical agents containing these derivatives
ES2070660A1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
NO176519C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske ketoner
LU90159I2 (fr) Difloxacin optionnellement sous forme d'un sel ou ester pharmaceutique
BR9609888A (pt) Halogenobenzimidazóis
MX9804107A (es) Derivados de quinolina.
IL114894A0 (en) Endothelin antagonists
CA2203274A1 (en) Apolipoprotein-b synthesis inhibitors
MY132062A (en) Apolipoprotein-b synthesis inhibitors
ES8406193A1 (es) Procedimiento para la preparacion de nuevas 1,4-dihidropiridinas sustituidas
DE69309454T2 (de) Pyridincarboximidamide und deren anwendung
ES2001703A6 (es) Procedimiento para la preparracion de derrrivados de acidos 2-(2-imidazolin -2-il)- piridin -3- carboxilicos.
IE870130L (en) Substituted 4-amino-3-hydroxybutyric acid derivatives,¹processes for their preparation, agents containing these¹compounds and their use
AU2175083A (en) 2-(substituted amino)-pyrimid-4-one derivatives
ES8801633A1 (es) Procedimiento para preparar nuevos derivados de 3-piridil-metilnaftilo
EP1227081A4 (en) PROCESS FOR THE PREPARATION OF OXYMINOALKANOIC ACID DERIVATIVES
ATE56967T1 (de) Amidderivate.
ATE58135T1 (de) 1,3-oxathianderivate.
WO1987004435A3 (en) Xanthine compounds
AU4878479A (en) Clavulanic acid derivatives
ZA914537B (en) N-oxyimidic acid derivatives
ES8306152A1 (es) Un procedimiento para la preparacion de nuevos derivados de 7-oxo-1-azabiciclo (3.2.0) hepteno.
ES8602620A1 (es) Un procedimiento de preparar derivados de acidos omega-((hi-droxi-2-fenil)-metilen-amino)-fenil-alcanocarboxilicos

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20080527